$724 Million Viral Clearance Market by Application, End User, Method, Viral Inactivation - Global Forecasts to 2023
DUBLIN, Sept. 25, 2018 /PRNewswire/ --
The "Viral Clearance Market by Application (Recombinant Proteins, Blood, Vaccines), End User (Pharmaceutical & Biotechnology Companies, CROs), Method (Viral Removal (Chromatography, Nanofiltration), Viral Inactivation (Low pH)) - Global Forecasts to 2023" report has been added to ResearchAndMarkets.com's offering.
The global viral clearance market is expected to reach USD 724.5 million by 2023 from an estimated USD 271.2 million in 2018, at a CAGR of 21.7% during the forecast period.
The growth of this market is primarily driven by factors such as the growth in the pharmaceutical and biotechnology industries, increasing number of new drug launches, R&D investments in life science, advancements in nanofiltration technology, and high incidence and large economic burden of chronic diseases.
The viral clearance market is segmented on the basis of application, end user, method, and region.
Based on application, the market is segmented into recombinant proteins, blood and blood products, vaccines, and other applications. The other applications segment is expected to grow at the highest CAGR during the forecast owing to the increasing use of cellular therapies in the treatment of various disorders, increasing public and private funding for stem cell research, rising awareness about stem cell therapies, and the use of tissue-based therapies to treat various diseases.
On the basis of end user, the viral clearance market is segmented into pharmaceutical & biotechnology companies, CROs, academic research institutes, and other end users. The contract research organizations segment is expected to register the highest CAGR during the forecast period. The high growth in this segment can be attributed to the ability of CROs to invest in extensive drug discovery infrastructure and the rising outsourcing of drug discovery services to CROs by pharmaceutical companies, academic institutes, small biotechnology companies, and start-ups.
On the basis of method, the global viral clearance market is segmented into two broad categories viral removal and viral inactivation. The viral removal segment is estimated to account for the largest share of the global viral clearance market in 2018. This segment is also expected to grow at the highest rate during the forecast period. The large share of this market segment is primarily attributed to the growth of R&D activities by biopharmaceutical companies; high acceptance of this method; and the accuracy, speed, and flexibility provided by the method in life sciences research.
The North American region is expected to account for the largest share of the market in 2018. The viral clearance market in the region is driven by the presence of national institutes supporting biotechnology and life science research, growth in the pharmaceuticals industry, and the increasing number of drug approvals. The rising prevalence of diseases, growing production of monoclonal antibodies, and government support for the development of drugs are some of the key factors driving the viral clearance market in the US. In Canada, increasing pharmaceutical production is expected to boost the growth of the viral clearance market.
However, Asia Pacific is expected to witness the highest growth during the forecast period, owing to increase in generics development and manufacturing, surge in funding for medical research and the presence of a large number of CROs to provide preclinical and clinical research services in China, government initiatives to boost the use of generic drugs, increasing aging population in Japan, rise in pharmaceutical R&D expenditures in India, and the growing pharmaceutical manufacturing in Singapore and Malaysia.
Viral Clearance Market
While this is a high-growth market, the high time and cost requirements for drug development may hamper the pace of activity in this sector, and consequently the adoption of viral clearance practices during the forecast period to a certain extent.
The key players in the global viral clearance market are Wuxi Biologics (Cayman) (China), Merck KGaA (Germany), Charles River Laboratories International Inc. (US), and Texcell Inc. (France). These companies together accounted for 70.0% of the global viral clearance market in 2017. Other players together accounted for 30.0% of the market. These include Kedrion (Italy), Vironova Biosafety (Sweden), Clean Cells (France), BSL BIOSERVICE Scientific Laboratories Munich GmbH (Germany), and ViruSure GmbH (Austria).
Key Topics Covered:
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights
4.1 Viral Clearance Market Overview
4.2 Asia Pacific: Viral Clearance Market, By Country and End User
4.3 Geographic Snapshot: Viral Clearance Market
4.4 Viral Clearance Market, By Application (2018 vs 2023)
5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Growth in the Pharmaceutical and Biotechnology Industries
5.2.1.2 Increasing Number of Drug Launches
5.2.1.3 Favorable R&D Investment Scenario
5.2.1.4 Possibility of Cell Culture Contamination
5.2.1.5 Advancements in Nanofiltration Technology
5.2.1.6 High Incidence and Large Economic Burden of Chronic Diseases
5.2.2 Restraints
5.2.2.1 Cost and Time-Intensive Drug Development Process
5.2.3 Opportunities
5.2.3.1 Increasing Pharmaceutical Outsourcing
5.2.3.2 Emerging Markets
5.2.4 Challenges
5.2.4.1 Dearth of Skilled Professionals
6 Viral Clearance Market, By Application
6.1 Introduction
6.2 Recombinant Proteins
6.3 Blood and Blood Products
6.4 Vaccines
6.5 Other Applications
7 Viral Clearance Market, By End User
7.1 Introduction
7.2 Pharmaceutical & Biotechnology Companies
7.3 Contract Research Organizations
7.4 Academic Research Institutes
7.5 Other End Users
8 Viral Clearance Market, By Method
8.1 Introduction
8.2 Viral Removal
8.2.1 Chromatography
8.2.2 Nanofiltration
8.2.3 Precipitation
8.3 Viral Inactivation
8.3.1 Low Ph
8.3.2 Solvent Detergent Method
8.3.3 Pasteurization
8.3.4 Other Viral Inactivation Methods
9 Viral Clearance Market, By Region
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 France
9.3.3 UK
9.3.4 RoE
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 RoAPAC
9.5 RoW
10 Competitive Landscape
10.1 Introduction
10.2 Viral Clearance Market Share Analysis (2017)
10.2.1 Wuxi Biologics (Cayman)
10.2.2 Merck KGaA
10.2.3 Charles River Laboratories International Inc.
10.3 Competitive Scenario
11 Company Profiles
11.1 Wuxi Biologics (Cayman) (Subsidiary of Wuxi Apptec)
11.2 Merck KGaA
11.3 Charles River Laboratories International
11.4 Kedrion
11.5 Vironova Biosafety
11.6 Texcell
11.7 Clean Cells
11.8 Bsl Bioservice
11.9 Virusure GmbH
For more information about this report visit https://www.researchandmarkets.com/research/s4pcn7/724_million?w=5
Media Contact:
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article